After expertly delivered #ESMO26 plenary, phase III Krascendo 1 study from Dr. @FSkoulidis now @NEJM. Divarasib superior with PFS 9.8m vs 5.7m (HR 0.58) and OS 17.7m vs 12m (HR 0.5

Stephen V Liu, MD· @StephenVLiu · X·2026-10-25 23:42· 1 天前评分70

正文 · 原文

After expertly delivered #ESMO26 plenary, phase III Krascendo 1 study from Dr. @FSkoulidis now @NEJM. Divarasib superior with PFS 9.8m vs 5.7m (HR 0.58) and OS 17.7m vs 12m (HR 0.56). RR 58% vs 32% and DOR 11.9m vs 6.9m. G3-4 TRAEs 25% vs 35%.

https://www.nejm.org/doi/full/10.1056/NEJMoa2605703

233 浏览 · 11 赞 · 4 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Stephen V Liu, MD · x.com